186374-96-9Relevant articles and documents
Catalytic nucleophilic fluorination by an imidazolium ionic liquid possessing trialkylphosphine oxide functionality
Paramanik, Minakshmi,Singh, Rekha,Mukhopadhyay, Sulekha,Ghosh, Sunil K.
, p. 47 - 55 (2015)
Abstract The synthesis of a new alkylmethylimidazolium ionic liquid wherein the alkyl group is functionalized with dihexylphosphine oxide moiety at the terminal position has been achieved in four steps from 1-methylimidazole. This hybrid ionic liquid effectively catalyzed the nucleophilic fluorination of primary alkyl mesylates under mild conditions using CsF as the fluoride source with a faster rate compared to butylmethylimidazolium mesylate. The hybrid catalyst was recycled 5 times without compromising the yield and purity of the product. The nucleophilic fluorination has been used for the synthesis of diethyl 2-(5-fluoropentyl)-2-methyl malonate, a precursor of 18F isotopomer of an apoptosis imaging agent and the protected form of O-(2'-fluoroethyl)-l-tyrosine, a 18F isotopomer of a tumor imaging agent.
COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS
-
, (2020/05/28)
This invention relates to certain compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat cancer. In another aspect, the disclosure relates to a pharmaceutical composition comprising a compound of Formula (1), For
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
-
Paragraph 0386; 0387; 0388, (2015/07/07)
A formulation comprising a modified synthetic messenger RNA and a delivery agent. The modified synthetic messenger RNA encodes a leptin protein, is non-replicating and is translation-ready. The formulation can be delivered to a subject with congenital leptin deficiency, lipodystrophy or other condition where circulating leptin level is low.
